Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
![Imatge de Publicacions](/sites/default/files/styles/3_1_small/public/2022-11/Portada_publicacions-petita_0.jpg?h=c6980913&itok=oZMso2V6)
Recent advances in combinatorial chemistry applied to development of anti-HIV drugs.
Resistencias a la terapia frente al virus de la hepatitis C
Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy.
HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
New targets and new drugs in the treatment of HIV.
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection.
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
[Mutations resulting in resistence of antiretroviral drugs in HIV-infected patients].
The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.